MeSH term
Frequency | Condition_Probility | ATP-Binding Cassette Transporters/*genetics | 39 | 17.0 |
Adult | 32 | 0.0 |
Aged | 26 | 0.0 |
Blotting, Southern | 2 | 0.0 |
*Gene Deletion | 2 | 0.0 |
Genotype | 15 | 0.0 |
Homozygote | 7 | 0.0 |
Humans | 253 | 0.0 |
Japan/epidemiology | 3 | 0.0 |
Lipoproteins, HDL/*blood | 7 | 3.0 |
Male | 62 | 0.0 |
Middle Aged | 32 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
Polymerase Chain Reaction | 10 | 0.0 |
ATP-Binding Cassette Transporters/genetics/*metabolism | 29 | 49.0 |
Animals | 117 | 0.0 |
Apolipoprotein A-I/blood | 5 | 4.0 |
Biological Transport, Active | 7 | 3.0 |
Cholesterol/metabolism | 50 | 16.0 |
Lipoproteins, HDL/blood | 3 | 1.0 |
Macrophages/metabolism | 20 | 6.0 |
Mice | 69 | 0.0 |
Mice, Knockout | 13 | 0.0 |
Mice, Transgenic | 9 | 0.0 |
Phospholipids/blood | 3 | 2.0 |
Research Support, Non-U.S. Gov't | 153 | 0.0 |
Tissue Distribution | 7 | 0.0 |
Anticholesteremic Agents/pharmacology | 8 | 18.0 |
Caco-2 Cells | 4 | 1.0 |
Cell Polarity | 2 | 1.0 |
*Gene Expression Regulation/drug effects | 3 | 1.0 |
Ligands | 13 | 0.0 |
Micelles | 3 | 6.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 5 | 3.0 |
Receptors, Retinoic Acid/*metabolism | 4 | 7.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 14 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 88 | 0.0 |
Retinoid X Receptors | 12 | 4.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
Tretinoin/pharmacology | 6 | 1.0 |
ATP-Binding Cassette Transporters/*chemistry/genetics/*metabolism | 2 | 50.0 |
Apolipoprotein A-I/chemistry/genetics/*metabolism | 2 | 40.0 |
Cell Line | 53 | 0.0 |
Cell Membrane/metabolism | 17 | 1.0 |
*Mutation | 12 | 0.0 |
Mutation, Missense | 4 | 0.0 |
Protein Binding | 23 | 0.0 |
Protein Structure, Tertiary | 17 | 0.0 |
Temperature | 2 | 0.0 |
Time Factors | 31 | 0.0 |
Transfection | 28 | 0.0 |
Apolipoprotein A-I/metabolism | 18 | 24.0 |
Blotting, Northern | 7 | 0.0 |
Comparative Study | 17 | 0.0 |
Rats | 10 | 0.0 |
Rats, Sprague-Dawley | 5 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*agonists | 4 | 23.0 |
Receptors, Retinoic Acid/*agonists | 2 | 66.0 |
Reverse Transcriptase Polymerase Chain Reaction | 21 | 0.0 |
Species Specificity | 3 | 0.0 |
Triglycerides/metabolism | 6 | 3.0 |
Biological Transport/*physiology | 2 | 20.0 |
Cholesterol/*metabolism | 63 | 24.0 |
Macrophages/*metabolism | 13 | 5.0 |
Models, Biological | 11 | 0.0 |
*Alternative Splicing | 3 | 0.0 |
DNA Primers | 6 | 0.0 |
Exons | 10 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*genetics | 2 | 2.0 |
Variation (Genetics) | 8 | 0.0 |
Amino Acid Sequence | 19 | 0.0 |
Cell Membrane/chemistry | 3 | 2.0 |
Cells, Cultured | 57 | 0.0 |
Fibroblasts/metabolism | 21 | 2.0 |
Macromolecular Substances | 3 | 0.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Molecular Sequence Data | 28 | 0.0 |
Precipitin Tests | 9 | 0.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Arteriosclerosis/*physiopathology | 2 | 11.0 |
Genome | 2 | 0.0 |
Lipoproteins, HDL/*genetics/*metabolism | 2 | 100.0 |
Particle Size | 3 | 1.0 |
Quantitative Trait, Heritable | 3 | 5.0 |
ATP-Binding Cassette Transporters/*metabolism | 27 | 33.0 |
Binding Sites | 4 | 0.0 |
Organ Specificity | 4 | 0.0 |
Phospholipids/*metabolism | 12 | 9.0 |
Skin/metabolism | 3 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 5 | 0.0 |
Lipoproteins, HDL Cholesterol/*metabolism | 3 | 8.0 |
Sensitivity and Specificity | 6 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 14 | 0.0 |
Tumor Cells, Cultured | 12 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
ATP-Binding Cassette Transporters/metabolism | 9 | 18.0 |
Receptors, Cytoplasmic and Nuclear/*physiology | 3 | 5.0 |
Transcription Factors/physiology | 3 | 1.0 |
Lipoproteins, HDL Cholesterol/blood/*deficiency | 3 | 100.0 |
Pedigree | 10 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Blotting, Western | 16 | 0.0 |
DNA Mutational Analysis | 7 | 0.0 |
Female | 39 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 11 | 1.0 |
Tangier Disease/*genetics | 4 | 80.0 |
Base Sequence | 25 | 0.0 |
Mutation | 33 | 0.0 |
Sequence Deletion | 3 | 0.0 |
ATP-Binding Cassette Transporters/chemistry/*metabolism | 3 | 30.0 |
Adenosine Triphosphate/*metabolism | 2 | 2.0 |
Cell Differentiation | 4 | 0.0 |
Cysteine Proteinase Inhibitors/pharmacology | 2 | 0.0 |
DNA, Complementary/metabolism | 6 | 0.0 |
Dose-Response Relationship, Drug | 26 | 0.0 |
Immunoblotting | 8 | 0.0 |
Leupeptins/pharmacology | 2 | 1.0 |
Lipids/metabolism | 23 | 7.0 |
5' Untranslated Regions | 2 | 1.0 |
Cohort Studies | 5 | 0.0 |
Coronary Arteriosclerosis/*genetics | 2 | 8.0 |
Gene Expression Regulation | 15 | 0.0 |
Lipids/*blood | 6 | 1.0 |
Models, Genetic | 3 | 0.0 |
Phenotype | 10 | 0.0 |
Polymorphism, Single Nucleotide | 5 | 0.0 |
Lipids/*metabolism | 16 | 6.0 |
Apolipoprotein A-I/*metabolism | 12 | 27.0 |
Biological Transport | 45 | 3.0 |
Choline/metabolism | 2 | 5.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Lipoproteins, HDL/*metabolism | 10 | 8.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Monocytes/metabolism | 5 | 1.0 |
Peptides/chemistry | 4 | 1.0 |
Biological Transport/physiology | 4 | 2.0 |
Lipoproteins, HDL/metabolism | 16 | 15.0 |
Liver/metabolism | 13 | 1.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 7 | 5.0 |
Tangier Disease/genetics/*metabolism | 3 | 100.0 |
ATP-Binding Cassette Transporters/*genetics/metabolism | 9 | 30.0 |
Adrenal Glands/metabolism | 2 | 4.0 |
In Situ Hybridization | 3 | 0.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Mice, Inbred C57BL | 16 | 0.0 |
Mice, Inbred CBA | 2 | 0.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 4 | 4.0 |
ATP-Binding Cassette Transporters/metabolism/*physiology | 4 | 57.0 |
*Phospholipid Transfer Proteins | 2 | 1.0 |
ATP-Binding Cassette Transporters/genetics | 7 | 10.0 |
Conserved Sequence | 2 | 0.0 |
Gene Deletion | 3 | 0.0 |
Macrophages, Peritoneal/metabolism | 2 | 8.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
RNA, Messenger/biosynthesis | 7 | 0.0 |
*Receptors, Cytoplasmic and Nuclear | 2 | 2.0 |
ATP-Binding Cassette Transporters/genetics/*physiology | 7 | 31.0 |
Oligonucleotides, Antisense/pharmacology | 4 | 1.0 |
Tangier Disease/blood | 2 | 50.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Hela Cells | 8 | 0.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Sterols/*metabolism | 3 | 9.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Transcription, Genetic/physiology | 2 | 1.0 |
Cysteine/genetics | 2 | 1.0 |
Dimerization | 4 | 0.0 |
In Vitro | 3 | 0.0 |
Kinetics | 11 | 0.0 |
Protein Structure, Secondary | 4 | 0.0 |
Case-Control Studies | 11 | 0.0 |
Lipoproteins, HDL Cholesterol/*blood | 10 | 4.0 |
Cyclic AMP/metabolism | 6 | 1.0 |
Fibroblasts/*metabolism | 3 | 1.0 |
Models, Chemical | 3 | 0.0 |
Phospholipids/metabolism | 22 | 11.0 |
RNA, Messenger/metabolism | 25 | 0.0 |
Up-Regulation | 15 | 0.0 |
Mass Fragmentography | 2 | 0.0 |
Genes, Reporter | 3 | 0.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 8 | 0.0 |
Receptors, Retinoic Acid/genetics/*metabolism | 3 | 10.0 |
Receptors, Thyroid Hormone/genetics/*metabolism | 2 | 9.0 |
ATP-Binding Cassette Transporters/biosynthesis/*genetics | 2 | 18.0 |
COS Cells | 2 | 0.0 |
Gene Expression | 8 | 0.0 |
Hydroxycholesterols/pharmacology | 8 | 28.0 |
Mutation/*genetics | 2 | 0.0 |
Receptors, Retinoic Acid/metabolism | 2 | 2.0 |
Thiazoles/pharmacology | 3 | 2.0 |
*Thiazolidinediones | 3 | 3.0 |
ATP-Binding Cassette Transporters/*biosynthesis/genetics | 4 | 23.0 |
Gene Expression/drug effects | 3 | 0.0 |
Alleles | 8 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Gene Frequency | 6 | 0.0 |
Introns | 8 | 0.0 |
Lipoproteins/*blood | 2 | 0.0 |
*Polymorphism, Genetic | 8 | 0.0 |
Arteriosclerosis/*metabolism | 3 | 4.0 |
Crosses, Genetic | 3 | 0.0 |
Diet | 3 | 0.0 |
Sex Factors | 5 | 0.0 |
Apolipoproteins E/*secretion | 2 | 40.0 |
Adenosine Triphosphate/metabolism | 5 | 1.0 |
Adenoviridae/genetics | 5 | 1.0 |
Plasmids/metabolism | 5 | 0.0 |
Receptors, LDL/metabolism | 2 | 2.0 |
Sterols/metabolism | 2 | 11.0 |
Transcription, Genetic | 8 | 0.0 |
Cell Line, Tumor | 7 | 0.0 |
Mevalonic Acid/metabolism | 2 | 20.0 |
Quinolines/*pharmacology | 2 | 6.0 |
Recombinant Proteins/genetics/metabolism | 4 | 0.0 |
Tangier Disease/genetics/metabolism | 8 | 88.0 |
Chromosomes, Artificial, Bacterial | 2 | 2.0 |
Coronary Disease/genetics | 2 | 5.0 |
Genetic Predisposition to Disease | 4 | 0.0 |
Heterozygote | 9 | 0.0 |
English Abstract | 4 | 0.0 |
Receptors, Cytoplasmic and Nuclear/agonists | 2 | 22.0 |
Signal Transduction | 5 | 0.0 |
Transcription Factors/agonists | 2 | 25.0 |
Apolipoprotein A-I/pharmacology | 5 | 50.0 |
Genetic Vectors | 4 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Monocytes/*metabolism | 2 | 0.0 |
Lipoproteins, LDL Cholesterol/metabolism | 3 | 8.0 |
ATP-Binding Cassette Transporters/*genetics/*metabolism | 6 | 42.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Sequence Alignment | 5 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 9 | 0.0 |
Receptors, Cytoplasmic and Nuclear/genetics/metabolism | 2 | 7.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Genes, Dominant | 3 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Antigens, CD36/genetics | 3 | 23.0 |
*Carrier Proteins | 2 | 0.0 |
Liver/*metabolism | 3 | 0.0 |
*Membrane Proteins | 11 | 1.0 |
Mice, Inbred DBA | 3 | 0.0 |
*Receptors, Immunologic | 10 | 6.0 |
Receptors, LDL/genetics | 3 | 4.0 |
Chromosome Mapping | 6 | 0.0 |
Japan | 5 | 0.0 |
Apolipoprotein A-I/drug effects/*metabolism | 2 | 100.0 |
Biological Transport/drug effects | 9 | 3.0 |
Hamsters | 11 | 0.0 |
Recombinant Proteins/metabolism | 7 | 0.0 |
Tangier Disease/metabolism | 2 | 50.0 |
CCAAT-Enhancer-Binding Proteins/metabolism | 2 | 4.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Glyburide/pharmacology | 6 | 31.0 |
Hypoglycemic Agents/pharmacology | 3 | 9.0 |
Lipoproteins, LDL/metabolism | 7 | 3.0 |
Phosphatidylserines/metabolism | 2 | 3.0 |
Protein Transport | 4 | 0.0 |
Tangier Disease/genetics | 8 | 100.0 |
Cholesterol/blood | 5 | 0.0 |
*Gene Expression | 2 | 0.0 |
*Receptors, Lipoprotein | 10 | 7.0 |
Triglycerides/blood | 6 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Brain/metabolism | 4 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Lung/metabolism | 2 | 1.0 |
Sequence Analysis, DNA | 10 | 0.0 |
Down-Regulation | 3 | 0.0 |
Fibroblasts | 4 | 0.0 |
Tritium | 2 | 0.0 |
Apolipoproteins/blood | 3 | 1.0 |
Lipids/blood | 7 | 1.0 |
Lipoproteins, HDL/blood/metabolism | 2 | 25.0 |
Lipoproteins, VLDL/metabolism | 4 | 3.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Tangier Disease/genetics/*metabolism/pathology | 2 | 100.0 |
Apolipoproteins/*genetics | 2 | 2.0 |
Anticholesteremic Agents/therapeutic use | 2 | 6.0 |
DNA/genetics | 2 | 0.0 |
Disease Progression | 3 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Models, Molecular | 4 | 0.0 |
Protein Conformation | 3 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Arteriosclerosis/metabolism | 3 | 5.0 |
CHO Cells | 6 | 0.0 |
Cell Compartmentation | 2 | 0.0 |
Endocytosis | 3 | 0.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Cyclodextrins/pharmacology | 2 | 7.0 |
*Gene Expression Regulation | 4 | 0.0 |
Gene Expression Regulation/physiology | 3 | 1.0 |
Molecular Structure | 2 | 0.0 |
*Variation (Genetics) | 4 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Chromatography, Liquid | 2 | 1.0 |
Circular Dichroism | 2 | 0.0 |
Lipoproteins/metabolism | 4 | 3.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Colonic Neoplasms/drug therapy/immunology/pathology/surgery/*therapy | 2 | 50.0 |
Disease-Free Survival | 2 | 0.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Follow-Up Studies | 3 | 0.0 |
Immunotherapy/*methods | 2 | 1.0 |
*Mycobacterium bovis | 2 | 22.0 |
Neoplasm Staging | 2 | 0.0 |
Odds Ratio | 3 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Risk Factors | 14 | 0.0 |
Semustine/administration & dosage | 2 | 40.0 |
Survival Analysis | 3 | 0.0 |
Treatment Outcome | 3 | 0.0 |
United States | 2 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Age Factors | 5 | 0.0 |
Body Mass Index | 6 | 0.0 |
Lipoproteins, HDL Cholesterol/metabolism | 9 | 18.0 |
Polymorphism, Genetic | 7 | 0.0 |
ATP-Binding Cassette Transporters/*physiology | 10 | 45.0 |
Receptors, Retinoic Acid/physiology | 2 | 8.0 |
RNA/metabolism | 2 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Linkage Disequilibrium | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Guanosine Triphosphate/metabolism | 2 | 0.0 |
Reference Values | 3 | 0.0 |
Foam Cells/*metabolism | 3 | 21.0 |
Transcription Factors/*agonists | 2 | 18.0 |
ATP-Binding Cassette Transporters/chemistry/genetics/*metabolism | 3 | 33.0 |
Apolipoproteins/*metabolism | 5 | 12.0 |
Protein Structure, Quaternary | 2 | 1.0 |
Tangier Disease/pathology | 2 | 100.0 |
Glomerular Mesangium/cytology/*metabolism | 2 | 8.0 |
Homeostasis/physiology | 2 | 3.0 |
Tangier Disease/*genetics/metabolism | 2 | 66.0 |
Anti-Bacterial Agents/pharmacology | 2 | 1.0 |
Membrane Microdomains/*metabolism | 2 | 4.0 |
Sphingomyelin Phosphodiesterase/pharmacology | 2 | 12.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Aging | 3 | 0.0 |
Child | 7 | 0.0 |
Hypolipoproteinemia/genetics | 3 | 75.0 |
Smoking | 2 | 0.0 |
Macrophages/cytology/metabolism | 2 | 8.0 |
Macrophages/cytology/*metabolism | 2 | 10.0 |
Lipoproteins/blood | 2 | 0.0 |
Phosphorylation | 9 | 0.0 |
Cyclodextrins/metabolism | 2 | 25.0 |
Receptors, Cytoplasmic and Nuclear/agonists/metabolism | 2 | 40.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Adolescent | 7 | 0.0 |
Child, Preschool | 3 | 0.0 |
Cholesterol/*blood | 2 | 0.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Apolipoprotein A-I/*pharmacology | 2 | 22.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Probability | 4 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Exons/genetics | 2 | 0.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Hydroxycholesterols/metabolism | 2 | 11.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
Neurons/metabolism | 2 | 0.0 |
Anticholesteremic Agents/*pharmacology | 2 | 6.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Trypsin/pharmacology | 2 | 1.0 |
*Genetic Predisposition to Disease | 4 | 0.0 |
Incidence | 2 | 0.0 |
Risk Assessment | 4 | 0.0 |
Foam Cells/metabolism | 2 | 15.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Protein Binding/drug effects | 2 | 0.0 |
Biotinylation | 2 | 1.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
RNA Processing, Post-Transcriptional | 2 | 1.0 |
Apolipoprotein A-I/*chemistry | 2 | 25.0 |
Macrophages/*drug effects/metabolism | 2 | 5.0 |
ATP-Binding Cassette Transporters/chemistry/*physiology | 4 | 100.0 |
Indoles/pharmacology | 2 | 0.0 |
Age of Onset | 2 | 0.0 |
Haplotypes | 4 | 0.0 |
Brefeldin A/pharmacology | 3 | 3.0 |
Biological Transport/genetics | 2 | 4.0 |
Kidney | 2 | 0.0 |
Gene Expression Regulation/drug effects/physiology | 2 | 3.0 |
Carrier Proteins/physiology | 2 | 1.0 |
ATP-Binding Cassette Transporters/*chemistry/metabolism | 2 | 33.0 |
Adenosine Triphosphate/chemistry | 2 | 8.0 |
Apolipoprotein A-I/chemistry | 2 | 25.0 |
Apolipoproteins E/chemistry | 2 | 50.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
Isoquinolines/pharmacology | 2 | 1.0 |
*Signal Transduction | 2 | 0.0 |
*Sulfonamides | 2 | 3.0 |
Tretinoin/metabolism | 2 | 5.0 |
ATP-Binding Cassette Transporters/blood/*genetics | 2 | 100.0 |
Flow Cytometry | 2 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Phosphatidylcholines/metabolism | 4 | 4.0 |
Sphingomyelins/metabolism | 5 | 17.0 |
Multivariate Analysis | 2 | 0.0 |
Sampling Studies | 2 | 1.0 |
Adenoviridae | 2 | 2.0 |
Cell Line, Transformed | 4 | 0.0 |
Protein Binding/physiology | 2 | 0.0 |
Transduction, Genetic | 2 | 0.0 |
Molecular Probe Techniques | 2 | 9.0 |
Liver/enzymology | 2 | 0.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Enzyme Activation | 3 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
rho GTP-Binding Proteins/metabolism | 2 | 2.0 |
Carrier Proteins/chemistry/*physiology | 2 | 5.0 |
ATP-Binding Cassette Transporters/genetics/metabolism | 2 | 7.0 |
Macrophages/drug effects/enzymology/*metabolism | 2 | 50.0 |
Receptors, LDL/genetics/metabolism | 2 | 9.0 |
Apolipoprotein A-I/metabolism/*physiology | 2 | 100.0 |
Apolipoproteins/metabolism | 2 | 5.0 |
Hydroxymethylglutaryl CoA Reductases/metabolism | 2 | 11.0 |
NIH 3T3 Cells | 2 | 0.0 |
Antigens, CD36/genetics/metabolism | 2 | 18.0 |
Homeostasis | 3 | 0.0 |
Polyisoprenyl Phosphates/metabolism | 2 | 40.0 |
*Transcription, Genetic | 2 | 0.0 |
Lipoproteins, HDL Cholesterol/*genetics/*metabolism | 2 | 100.0 |
Antilipemic Agents/pharmacology | 2 | 14.0 |
Bezafibrate/pharmacology | 2 | 28.0 |
Protein Isoforms | 2 | 0.0 |
Antigens, CD36/physiology | 2 | 11.0 |
Tangier Disease/blood/genetics/*metabolism | 2 | 100.0 |
DNA, Complementary/isolation & purification | 2 | 1.0 |
Lipoproteins, HDL Cholesterol/*blood/genetics | 2 | 25.0 |
*Ethics Committees, Research | 2 | 66.0 |
*Ethics, Research | 2 | 28.0 |
Human Experimentation | 2 | 40.0 |
Prisoners | 2 | 40.0 |
Public Health/*ethics | 2 | 66.0 |
Role | 2 | 50.0 |
Apolipoproteins B/metabolism | 2 | 2.0 |
Lipoproteins, HDL/*physiology | 2 | 20.0 |
Structure-Activity Relationship | 3 | 0.0 |
Hydroxycholesterols/*pharmacology | 2 | 28.0 |
Tretinoin/*pharmacology | 2 | 0.0 |
Hepatocytes/*metabolism | 2 | 4.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
